Van Lanschot Kempen Investment Management N.V. Boosts Stake in Abbott Laboratories $ABT

Van Lanschot Kempen Investment Management N.V. increased its position in Abbott Laboratories (NYSE:ABT) by 83.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 188,796 shares of the healthcare product maker’s stock after purchasing an additional 85,931 shares during the period. Van Lanschot Kempen Investment Management N.V.’s holdings in Abbott Laboratories were worth $23,654,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. MidAtlantic Capital Management Inc. purchased a new stake in shares of Abbott Laboratories in the 4th quarter valued at about $25,000. Harbor Capital Advisors Inc. purchased a new stake in Abbott Laboratories during the 4th quarter valued at approximately $27,000. Intesa Sanpaolo Wealth Management purchased a new stake in Abbott Laboratories during the 4th quarter valued at approximately $29,000. Bridge Generations Wealth Management LLC purchased a new stake in Abbott Laboratories during the 3rd quarter valued at approximately $33,000. Finally, Prudent Man Investment Management Inc. purchased a new stake in Abbott Laboratories during the 4th quarter valued at approximately $33,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ABT has been the subject of several analyst reports. JPMorgan Chase & Co. reduced their price objective on Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. BTIG Research reaffirmed a “buy” rating and set a $131.00 price objective on shares of Abbott Laboratories in a research note on Monday, April 27th. Stifel Nicolaus reduced their price objective on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, April 17th. TD Cowen reduced their price objective on Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Finally, UBS Group reduced their price objective on Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating for the company in a research note on Monday, April 20th. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, Abbott Laboratories currently has an average rating of “Moderate Buy” and a consensus target price of $118.38.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $87.89 on Friday. The company has a market cap of $153.08 billion, a price-to-earnings ratio of 24.62, a price-to-earnings-growth ratio of 1.50 and a beta of 0.63. The stock has a 50 day simple moving average of $91.46 and a 200-day simple moving average of $107.98. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $139.06. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. The business had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The company’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the prior year, the business posted $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, equities analysts forecast that Abbott Laboratories will post 5.48 EPS for the current year.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott declared its 410th consecutive quarterly dividend, underscoring its long track record of returning cash to shareholders. The board approved a 63-cent per share quarterly dividend. Abbott declares 410th consecutive quarterly dividend
• Positive Sentiment: Erste Group Bank nudged its FY2026 EPS estimate higher for Abbott, aligning with the current consensus of $5.48 per share, which suggests analysts still see stable earnings power.
• Positive Sentiment: Abbott also continues to highlight growth opportunities in diabetes care and medtech, including an expanded MiniMed collaboration and recent CE Mark approval for Libre Duo, supporting the company’s innovation story.
• Neutral Sentiment: Research coverage remains mixed, with one Seeking Alpha piece calling Abbott “structurally undervalued,” but this is opinion-based and not a direct catalyst. Abbott Laboratories Remains Structurally Undervalued
• Neutral Sentiment: Erste Group also trimmed its FY2027 EPS estimate slightly to $6.04 from $6.05, a very small revision that should have limited impact on sentiment.
• Neutral Sentiment: Star51 Capital’s first close of its medtech fund included Abbott as a lead backer, reinforcing Abbott’s strategic interest in healthcare innovation, though the direct stock impact is likely modest.
• Negative Sentiment: BofA cut its price target on Abbott from $120 to $102, signaling less upside than before and likely adding to investor caution. BofA adjusts price target on Abbott Laboratories to 102 from 120
• Negative Sentiment: Recent trading has shown Abbott slipping more than the broader market, reflecting ongoing weakness in the shares and investor concern over valuation versus slower near-term momentum. Abbott (ABT) Dips More Than Broader Market
• Negative Sentiment: Portfolio filings showing Elfun Trusts exited Abbott may also add a small amount of selling pressure, though this is not a major fundamental development. Elfun Trusts Exits Abbott Laboratories

Insider Buying and Selling

In other Abbott Laboratories news, Director Daniel J. Starks bought 10,000 shares of the business’s stock in a transaction dated Monday, April 27th. The stock was acquired at an average cost of $92.65 per share, with a total value of $926,500.00. Following the purchase, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This represents a 0.15% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Philip P. Boudreau bought 2,200 shares of the business’s stock in a transaction dated Thursday, April 23rd. The shares were acquired at an average cost of $91.50 per share, with a total value of $201,300.00. Following the completion of the purchase, the chief financial officer owned 2,200 shares in the company, valued at approximately $201,300. This represents a ? increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.